As previously reported, Guggenheim analyst Seamus Fernandez initiated coverage of Mineralys Therapeutics (MLYS) with a Buy rating and $32 price target. The firm sees "multibillion-dollar potential" for ASIs, a novel drug class for the treatment of uncontrolled and resistant hypertension, and notes that Mineralys’ product candidate, lorundrostat, is initiating its pivotal program with a Phase 2 trial in the first half of this year, followed by a larger Phase 3 trial in the second half. The firm is "optimistic" on the clinical and commercial potential of lorundrostat due to what it sees as the "strong scientific rationale" for the role of aldosterone in hypertension, the company’s high quality clinical trial design, and the "strategic validation" of the ASI class demonstrated by AstraZeneca’s (AZN) recent acquisition of CinCor Pharma.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MLYS:
- BofA starts Mineralys Therapeutics at Buy with $39 price target
- Mineralys Therapeutics initiated with an Outperform at Evercore ISI
- Mineralys Therapeutics initiated with an Overweight at Wells Fargo
- Mineralys Therapeutics initiated with an Outperform at Credit Suisse
- Mineralys Therapeutics initiated with a Buy at Guggenheim